Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
Samuel Ponce‐de‐León, Martha Torres, Luis Enrique Soto-Ramírez, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 25

Showing 25 citing articles:

Vaccine adjuvants for infectious disease in the clinic
Morgan Goetz, Naaz Thotathil, Zongmin Zhao, et al.
Bioengineering & Translational Medicine (2024) Vol. 9, Iss. 4
Open Access | Times Cited: 8
Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges
Bryce M. Warner, Jacob G. E. Yates, Robert Vendramelli, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice
Stefan Slamanig, Irene González‐Domínguez, Lauren A Chang, et al.
EBioMedicine (2024) Vol. 105, pp. 105185-105185
Open Access | Times Cited: 5
Next-Generation Coronavirus Disease 2019 Vaccines
Kathryn E. Stephenson
Infectious Disease Clinics of North America (2025)
Closed Access
Durability of immune responses to SARS-CoV-2 infection and vaccination
Mehul S. Suthar
Seminars in Immunology (2024) Vol. 73, pp. 101884-101884
Closed Access | Times Cited: 4
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates
Matthew Gagné, Barbara J. Flynn, Shayne F. Andrew, et al.
Nature Immunology (2024) Vol. 25, Iss. 10, pp. 1913-1927
Open Access | Times Cited: 3
Mucosal Vaccination with a Newcastle Disease Virus-Vectored Vaccine Reduces Viral Loads in SARS-CoV-2-Infected Cynomolgus Macaques
Bryce M. Warner, Mable Chan, Nikesh Tailor, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 404-404
Open Access | Times Cited: 2
Mucosal prime-boost immunization with live murine pneumonia virus-vectored SARS-CoV-2 vaccine is protective in macaques
Jaclyn A. Kaiser, Christine E Nelson, Xueqiao Liu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Viral-vectored respiratory mucosal vaccine strategies
Mangalakumari Jeyanathan, Sam Afkhami, Alisha Kang, et al.
Current Opinion in Immunology (2023) Vol. 84, pp. 102370-102370
Closed Access | Times Cited: 7
Advantages and challenges of Newcastle disease virus as a vector for respiratory mucosal vaccines
Rik L. de Swart, George A. Belov
Current Opinion in Virology (2023) Vol. 62, pp. 101348-101348
Closed Access | Times Cited: 7
Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates
Matthew Gagné, Barbara J. Flynn, Shayne F. Andrew, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
A Phase II Study Integrating a Single-Blind Safety Phase with a Double-Blind, Placebo-Controlled Randomized Phase, Assessing Single-Dose Intramuscular or Intranasal Administration to Evaluate the Safety and Immunogenicity of the Recombinant Vaccine Against COVID-19 (AVX/COVID-12 “Patria”) Based on an Active Newcastle Disease Viral Vector as a Heterologous Booster in Subjects with Evidence of Previous Immunity to SARS-CoV-2
Constantino López‐Macías, Martha Torres, Brenda Armenta-Copca, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Phase II/III Double-Blind Study Evaluating Safety and Immunogenicity of a Single Intramuscular Booster Dose of the Recombinant SARS-CoV-2 Vaccine “Patria” (AVX/COVID-12) Using an Active Newcastle Disease Viral Vector (NDV) during the Omicron Outbreak in Healthy Adults with Elevated Baseline Antibody Titers from Prior COVID-19 and/or SARS-CoV-2 Vaccination
Constantino López‐Macías, Martha Torres, Brenda Armenta-Copca, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals
Alejandro Torres-Flores, Luis Ontiveros‐Padilla, Ruth L. Madera-Sandoval, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview
Ruth Henríquez, Isabel Muñoz‐Barroso
Heliyon (2024) Vol. 10, Iss. 15, pp. e34927-e34927
Open Access | Times Cited: 1
Next Generation RNA/Protein‐Carrying Vector With Pleiotropic Activity
Tetsuya Nosaka, Junpei Ohtsuka, Tomomi Ohtsuka, et al.
Reviews in Medical Virology (2024) Vol. 34, Iss. 6
Open Access | Times Cited: 1
Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate AVX/COVID-12 Activates T Cells and Is Recognized by Antibodies from COVID-19 Patients and Vaccinated
Alejandro Torres-Flores, Luis Ontiveros‐Padilla, Ruth L. Madera-Sandoval, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Nanoparticle-Mediated Mucosal Vaccination: Harnessing Nucleic Acids for Immune Enhancement
Wajid Hussain, Sadia Chaman, Hafiza Nazia Koser, et al.
Current Microbiology (2024) Vol. 81, Iss. 9
Closed Access
Validation of the Enzyme-Linked ImmunoSpot Analytic Method for the Detection of Human IFN-γ from Peripheral Blood Mononuclear Cells in Response to the SARS-CoV-2 Spike Protein
Laura E. Carreto-Binaghi, Milton Nieto-Ponce, Andrea Palencia-Reyes, et al.
Biomolecules (2024) Vol. 14, Iss. 10, pp. 1286-1286
Open Access
Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 “Patria” recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico
Constantino López‐Macías, Martha Torres, Brenda Armenta-Copca, et al.
Vaccine (2024) Vol. 43, pp. 126511-126511
Closed Access
Newcastle Disease Virus Expressing Cap Gene of Porcine Circovirus Type 2 Confers Protection in Mice and Induced Long-Lasting Neutralizing Antibodies in Pigs
Sohini Dey, Rudhreswaran Murugasamy, Lukumoni Buragohain, et al.
Vaccines (2024) Vol. 12, Iss. 11, pp. 1285-1285
Open Access
A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge
Stefan Slamanig, Nicholas Lemus, Tsoi Ying Lai, et al.
Vaccine (2024) Vol. 45, pp. 126586-126586
Closed Access
Early evolution of mumps-HCV chimeric viruses in Vero cells induces loss of HCV gene expression and promotes accumulation of substitutions uncharacteristic of mumps strains
Dorotea Pali, Dubravko Forčić, Maja Jagušić, et al.
Virology (2024) Vol. 603, pp. 110379-110379
Closed Access
Newcastle Disease Virus Displaying an Ectodomain of Middle East Respiratory Syndrome Coronavirus Spike Protein Elicited Robust Humoral and Cellular Immunity in Mice
Jaturawitt Prasopsiri, Kanjana Srisutthisamphan, Benjamas Liwnaree, et al.
Vaccines (2024) Vol. 13, Iss. 1, pp. 2-2
Open Access
Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern
Gabriel Diem, Stefanie Dichtl, Viktoria Zaderer, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 5
Open Access | Times Cited: 1
Page 1

Scroll to top